Amgen Inc. (AMGN) Stock Analysis
Is AMGN a good investment?
Amgen Inc. (AMGN) has a Plutrex AI rating of 32.0/100 as of November 12, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Exceptional FCF moat of $9.58B annually (net margin 24.1% vs. industry 15.9%, +51% premium) funds full debt service on $24-25B net debt, $4B+ annual dividend, and ongoing buybacks simultaneously — a fortress cash generation capability matched by virtually no peer. Main concern: Severe price-to-fair-value gap: at $468.11, AMGN is 9.4% above analyst consensus of $428.06, 37-65% above DCF-implied intrinsic value range of $280-$340, and 95-146% above pure growth-adjusted fair value ($190-$240 at 1.5-2.0x PEG). No margin of safety exists — the stock has zero buffer against any negative catalyst.
Investment Summary
AMGN is a world-class biologic drug manufacturer trading at a price that is fundamentally unjustifiable given its forward growth profile. At $468.11, the stock is now 9.4% ABOVE the analyst consensus target of $428.06 — which itself embeds generous assumptions. The PEG ratio of 3.81 (improved from 4.77 prior, but still extreme) means investors are paying nearly 4x the forward growth rate. With 5-year EPS growth of only 7.1% and next-year EPS growth of 6.3%, a P/E of 27.15x is fundamentally unsupported. The stock's exceptional profitability (gross margin 74.0%, operating margin 34.1%, FCF $9.58B, ROE 78.3%) earns it a quality premium — but not THIS premium. Positively, the PEG has contracted 20% from 4.77 to 3.81 (analyst target rose 5.8% from $404.61 to $428.06, partially closing the valuation gap), and Q3 2026 results have been released. News is overwhelmingly positive: Sjogren's late-stage trial success (headline: 'Amgen's experimental Sjogren's drug meets late-stage trial goal'), strong Repatha data at AHA 2026, and dividend growth recognition. However, positive news cannot overcome a 9.4% premium to consensus, 4.27x the industry D/E (3.60 vs. 0.844 peer average), and forward growth 53.5% below peers. SELL recommendation maintained — no entry until $290-$315 zone.
Key Strengths
- Exceptional FCF moat of $9.58B annually (net margin 24.1% vs. industry 15.9%, +51% premium) funds full debt service on $24-25B net debt, $4B+ annual dividend, and ongoing buybacks simultaneously — a fortress cash generation capability matched by virtually no peer
- Pipeline optionality emerging: Sjogren's late-stage trial success (headline: 'Amgen's experimental Sjogren's drug meets late-stage trial goal') and Repatha AHA 2026 cost-effectiveness data (headline: 'NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER') represent incremental catalysts that could accelerate consensus EPS estimates beyond the current 6.3-7.1% forward growth assumptions
- Relative valuation vs. peers is paradoxically attractive: PE of 27.15x is 18.3% below industry average of 33.24x, and PEG of 3.81 is 58.2% below industry PEG of 9.13 — meaning in the context of a sector priced for extreme speculation, AMGN's operational quality is modestly discounted
Key Concerns
- Severe price-to-fair-value gap: at $468.11, AMGN is 9.4% above analyst consensus of $428.06, 37-65% above DCF-implied intrinsic value range of $280-$340, and 95-146% above pure growth-adjusted fair value ($190-$240 at 1.5-2.0x PEG). No margin of safety exists — the stock has zero buffer against any negative catalyst
- Extreme leverage at the slowest-growth position in the sector: D/E of 3.60x is 4.27x the industry average (0.844x), and 5-year forward EPS growth of 7.1% is 53.5% below the peer average of 15.3%. This creates the worst risk-adjusted profile in the peer group — maximum financial risk paired with minimum growth reward. Any interest rate spike or revenue shortfall (e.g., biosimilar erosion of key biologics) could force dividend cuts and credit rating pressure
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
AMGN's fundamentals present a stark duality. Profitability is exceptional: gross margin 74.0% (vs. industry 71.7%), operating margin 34.1% (matches industry best), net margin 24.1% (vs. industry 15.9%, a +51% premium), ROE 78.3% (vs. industry 22.9%, +242% premium), and FCF of $9.58B — one of the largest absolute FCF generators in biopharma. These are genuinely elite metrics. However, the growth engine is decelerating: forward EPS growth of 6.3% (next year) and 7.1% (5-year) versus historical earnings growth of 19.4% represents a 63-67% deceleration. Revenue growth is slowing to 8.5% (vs. 15.9% industry average). The valuation math is damning: P/E of 27.15x on 7.1% growth implies a PEG of 3.81 — a fair-value PEG of 1.5-2.0x (applying quality premium) would justify P/E of 11-14x, implying intrinsic value of $190-$240. Even at a generous DCF ($9.58B FCF, 7% growth, 9% discount rate), intrinsic value converges around $280-$340. Financial health is a critical concern: D/E of 3.60x is 326.7% above the industry average of 0.844x — the Horizon acquisition debt remains a substantial burden. Cash of $13.19B provides liquidity, but net debt is approximately $24-25B. The valuation score of 12/100 and health score of 30/100 appropriately anchor the negative thesis despite perfect profitability.
News Sentiment
Amgen is having a banner news cycle — but investors shouldn't mistake good headlines for a good stock price. The biotech giant, which has been quietly building one of the most reliable dividend machines in pharmaceuticals (its payout has grown 800% since 2011), just delivered a string of encouraging clinical and commercial data that's turning heads on Wall Street. At a major medical conference, new data demonstrated that Repatha, Amgen's cholesterol-fighting blockbuster, is most effective when started earlier in cardiovascular disease — a finding that could unlock thousands of new patients for the drug and strengthen the case for insurance coverage. Meanwhile, Amgen's experimental treatment for Sjogren's syndrome — a painful autoimmune disease affecting millions — just cleared a critical late-stage clinical trial, putting Amgen in direct competition with Novartis for a market with limited existing options. The drug, described in headlines as 'Novartis-rivaling,' represents exactly the kind of pipeline firepower bulls are counting on to reignite growth beyond the current 7% EPS trajectory. Amgen also released its Q3 2026 financial results, and analysts continue to flag it as one of the few biotechs that reliably raises dividends through every market cycle. The challenge? All this good news is already baked into a stock trading 9% above what analysts think it's worth. Great company, great pipeline — but at $468, the price may be the biggest risk of all.
Risk Assessment
PRIMARY RISK (Valuation): At $468.11, AMGN is priced for perfection with no margin of safety. Any disappointment in biosimilar competition (Enbrel, Prolia erosion), patent cliff acceleration, or Horizon integration shortfalls could trigger a 20-35% correction toward analyst consensus ($428) or further toward intrinsic value ($280-$340). SECONDARY RISK (Leverage): D/E of 3.60x ($24-25B net debt) means a 1% rise in refinancing rates adds ~$240-250M in annual interest expense — meaningful against $9.58B FCF but psychologically negative for sentiment. TERTIARY RISK (Growth deceleration): Historical EPS growth of 19.4% decelerating to 6.3-7.1% forward is not fully priced in at 27.15x P/E. If consensus further downgrades to 5% growth, fair P/E falls to ~10-12x, implying $163-$195 — catastrophic downside. MITIGATION: Pipeline optionality (Sjogren's approval, IMDELLTRA expansion, Repatha label expansion) could add $1-3/share to EPS estimates. FCF of $9.58B provides deleveraging runway — D/E should normalize toward 2.0x within 3-4 years organically. If entered at $290-$315, risk/reward improves dramatically with upside to analyst consensus of $428 representing 36-48% return.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is AMGN a halal stock?
No, Amgen Inc. (AMGN) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for AMGN?
Amgen Inc. (AMGN) has a Plutrex AI rating of 32.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is AMGN a good investment?
According to Plutrex AI, AMGN has a Sell rating (32.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in AMGN?
US stocks like AMGN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in AMGN?
Plutrex AI identifies the main risks for AMGN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.